Biotechnology ETFs Raise Hopes On Stock Jump

February 08, 2008 at 10:00 am by Tom Lydon      Bookmark and Share

4187467410 Biotechnology exchange traded funds (ETFs) and stocks are thriving as fourth quarter earnings from Biogen Idec Inc. (BIIB) gave investors an 84% jump in profit.

According to the Associated Press, Biogen’s profits rose on news of sales of its multiple sclerosis drug Avonex and Rituxan, which treats non-Hodgkins lymphoma and rheumatoid arthrities. Rituxan is co-promoted by Genentech (DNA).

Biotech ETFs that could get a lift on the good news:

  • iShares Nasdaq Biotechnology (IBB):  Biogen holds 4%; down 4.1% year-to-date
  • Biotech HOLDRs (BBH): Biogen, 9.3%;Genentech, 36.6%; up 1% year-to-date
  • SPDR S&P Biotech (XBI): Biogen, 3.5%; Genentech, 3.5%; down 6% year-to-date
  • First Trust Amex BiotechnologyIndex ETF (FBT): Biogen, 3.8%; Genentech, 4.7%; down 6.6% year-to-date
  • PowerShares Dynamic Biotech & Genome (PBE): Biogen 3.9%; Genentech 4.4%; down 7.9% year-to-date
Share this post:
  • email
  • Yahoo! Buzz
  • Digg
  • del.icio.us
  • Tipd
  • Reddit
  • StumbleUpon
  • Facebook
  • Technorati
  • Google Bookmarks
  • TwitThis

Tags: ,

Subscribe to Our Daily E-mail Newsletter

Enter your e-mail address below to sign up for our daily e-mail newsletter, the Daily Market Update. We will never share your e-mail address with third parties.

Subscribe to Our RSS Feed

Click here to subscribe to our RSS feed

blog comments powered by Disqus
Special Report

Recent TV Appearances

Now Available:

The ETF Trend
Following Playbook

ETF Trends' new book is now available. Click here for details. Or order online from one of these bookstores:
Amazon        Barnes and Noble


iMoney

ETF Trends' book iMoney is available. Click here for details. Or order online from one of these bookstores:
Amazon        Amazon